CORRADINI, PAOLO
CORRADINI, PAOLO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study
2026 G. Gabrielli, B. Casadei, A. Chiappella, M.C. Tisi, E. Galli, I. Cutini, A. Di Rocco, L. Donzelli, M. Martino, G. Policastro, A. Crescimanno, G. Petruzzellis, F. Stella, C. Visco, M. Krampera, M. Farina, P. Angelillo, L. Brunello, B. Bruno, D. Mannina, M. Novo, G. Grillo, L. Argnani, F. Bonifazi, P. Corradini, P.L. Zinzani
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study
2026 N. Polverelli, C. Zerbi, M.G. Benevento, M. Algeri, A. Algarotti, E. Angelucci, A.C. Balduzzi, M. Basiricò, S. Bassi, G. Battipaglia, E. Benedetti, A. Biffi, F. Bonifazi, C. Borghero, S. Bramanti, L. Brunello, P. Bresciani, A. Busca, R. Cairoli, P. Carluccio, F. Carobolante, A.M. Carella, I.M. Cavattoni, R. Cerretti, A. Chiappella, P. Chiusolo, M. Cimminiello, P. Corradini, A. Crescimanno, A. Cuoghi, N. Di Renzo, F. Fagioli, R. Fanin, M. Faraci, V. Federico, A. Geromin, L. Giaccone, A. Giacomazzi, A. Grassi, G. Grillo, A. Imovilli, C. Ingrosso, A.P. Iori, G. La Nasa, S. Leotta, M.T. Lupo Stanghellini, G. Mancini, J. Mariotti, A. Mele, M. Menconi, F. Merli, N. Mordini, M. Musso, C. Nozzoli, F. Pane, M. Parma, R. Pastano, D. Pastore, F. Patriarca, A. Picardi, S. Piemontese, A. Pierini, E. Piras, F. Porta, G. Porto, A. Prete, L. Prezioso, A. Proia, A. Raiola, R. Ricci, M. Roberto, C. Rosignoli, D. Russo, D. Salvatore, S. Santarone, G. Saporiti, F. Saraceni, C. Selleri, B. Serio, C. Skert, S. Sica, A. Spina, F.P. Tambaro, C. Tecchio, E. Terruzzi, M. Tumino, D. Vallisa, F. Zallio, M. Zecca, A. Taurino, A. Bianchessi, I. Defrancesco, G. Losi, E. Degrandi, M. Malagola, L. Castagna, M. Martino
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study
2026 A. Barone, F. Stella, S. Ljevar, B. Casadei, S. Bramanti, P. Chiusolo, A.D. Rocco, M.C. Tisi, I. Cutini, P. Angelillo, M. Martino, M. Musso, M. Farina, M. Pennisi, A.M. Barbui, R. Freilone, J. Olivieri, G. Grillo, P. Musto, F. Saraceni, M. Krampera, L. Brunello, A. Castellino, S. Ragaini, L. Arcaini, A. Chiappella, A. Guidetti, A. Dodero, R. Miceli, P. Zinzani, P. Corradini
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
2026 R.T. Maziarz, M.R. Bishop, C.S. Tam, P. Borchmann, N. Worel, J.P. Mcguirk, H. Holte, E.K. Waller, S. Jaglowski, C. Andreadis, S.R. Foley, J.R. Westin, I. Fleury, P.J. Ho, S. Mielke, T. Teshima, M. Janakiram, J. Hsu, K. Izutsu, M.J. Kersten, M. Ghosh, N. Wagner-Johnston, K. Kato, P. Corradini, W. Ma, X. Han, M. Nuortti, R. Awasthi, K.E. Mundt, M. Majdan, H.J. Maier, A. Jegerlehner, G. Salles, S.J. Schuster
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study
2026 L. Farina, A. Noto, A. Aiello, M. Motta, A. Ferrario, R. Moia, L. Scarfò, M. Deodato, M. Merli, S. Ljevar, G. Pruneri, C. Carniti, P. Corradini
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
2026 H. Einsele, J. San-Miguel, B. Dhakal, C. Touzeau, X. Leleu, N.W. Van De Donk, S. Sidana, A. Oriol, Y.C. Cohen, S.J. Harrison, M. Mateos, J. Martínez-López, P. Corradini, L. Karlin, D. Chen, Q. Li, T. Yeh, K. Li, V. Plaks, A. Slaughter, C. Lonardi, N. Benachour, A. Ghosh, M. Vogel, J.M. Schecter, N. Lendvai, M. Koneru, N. Patel, E. Florendo, P.J. Ho, R. Popat
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
2025 G. Damaj, A. Bazarbachi, P. Berning, A. Cottereau, C.P. Fox, C. Kyriakou, K. Cwynarski, P. Zinzani, O. Tournilhac, W. Jurczak, I.E. Karsten, F. Wang, A. Marcais, A. Tanase, S. Nguyen-Quoc, Y. Serroukh, M. Aljurf, D. Beauvais, G. Wulf, A. Sureda, P. Corradini, O. Hermine, M. Hamadani, F. Onida, A.L. Ruggeri, I. Sanchez-Ortega, I. Yakoub-Agha, P. Dreger, N. Schmitz
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
2025 F. Stella, A. Chiappella, M. Magni, F. Bonifazi, C. De Philippis, M. Musso, I. Cutini, S. Ljevar, A.M. Barbui, M. Farina, M. Martino, M. Massaia, G. Grillo, P. Angelillo, B. Botto, F. Patriarca, M. Krampera, L. Arcaini, M.C. Tisi, P. Zinzani, F. Sorà, S. Bramanti, M. Pennisi, C. Carniti, P. Corradini
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
2025 C. Papayannidis, E. Petracci, P. Zappasodi, N. Fracchiolla, F. Ciceri, C. Sartor, E. Roncoroni, F. Di Raimondo, D. Mattei, M.B. Giannini, F. Lanza, M. Gottardi, M.I. Del Principe, E. Borlenghi, M. Fumagalli, D. Vallisa, S. Sica, N. Di Renzo, F. Fabbiano, E. Todisco, P. de Fabritiis, M. Luppi, F. Passamonti, P. Corradini, F. Petruzziello, F. Pane, F. Ferrara, G. Mambelli, R. Volpi, F. Frabetti, C. Zingaretti, G. Marconi, G. Martinelli
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial
2025 R. Durmo, S. Chauvie, C. Minoia, F. Bergesio, F. Fallanca, S. Peano, L. Marcheselli, A. Anastasia, C. Boccomini, P. Corradini, J. Olivieri, L. Arcaini, F. Cavallo, A. Ibatici, L. Nassi, V. Tarantino, A. Pinto, C. Stelitano, A. Pulsoni, F. Ricci, S. Mancuso, E. Cencini, N. Di Renzo, C. Mannarella, A. Palmas, P. Zinzani, C. Bocci, F. Rossi, A.M. Carella, M. Federico, A. Versari, L. Guerra, S. Luminari
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
2025 N. Puig, J. Diels, S. Van Sanden, J. Mendes, H. Burnett, A. Cichewicz, S. Lee, T. Hernando, J.M. Schecter, N. Lendvai, N. Patel, J.M. Sanchez-Pina, S. Rocchi, R. Mina, P. Corradini, M. Cavo, J.S. Miguel, L. Shune, A.M. Khan, S. Sidana, X. Leleu, S. Manier, B. Lipe, K. Weisel, J. Martinez-Lopez
Prospective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study
2025 F. Stella, M. Pennisi, A. Chiappella, B. Casadei, S. Bramanti, S. Ljevar, P. Chiusolo, A.D. Rocco, M.C. Tisi, P. Angelillo, I. Cutini, M. Martino, A. Barone, F. Bonifazi, A. Santoro, F. Sorà, M. Novo, A.M. Barbui, D. Russo, M. Musso, G. Grillo, M. Krampera, J. Olivieri, L. Brunello, F. Cavallo, M. Massaia, L. Arcaini, L. Farina, P. Zinzani, R. Miceli, P. Corradini
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
2025 A. Barone, C. De Philippis, F. Stella, A. Dodero, B. Sarina, M. Pennisi, A. Santoro, C. Carlo-Stella, A. Guidetti, S. Bramanti, P. Corradini
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries
2025 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Corradini, P. Russo
Prognostic role of interim PET in patients with follicular lymphoma: a post-hoc study of FOLL12 trial by FIL
2025 R. Durmo, S. Chauvie, F. Fallanca, F. Bergesio, A. Pinto, I. Del Giudice, M. Coscia, P. Corradini, E. Angelucci, P. Tosi, R. Freilone, F. Ballerini, A. Bari, D. Pastore, P.L.L. Zinzani, S.A.M. Bolis, L. Flenghi, A. Liso, J. Olivieri, L. Marcheselli, M. Merli, A. Versari, L. Guerra, S. Luminari
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries
2025 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Zinzani, P. Corradini, P. Russo
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
2025 S. Viviani, C. Pavoni, S.F. Barrington, L. Guerra, H. Schöder, P. Johnson, A.A. Kirkwood, D.M. Stephens, J.W. Friedberg, S. Chauvie, M.V. Knopp, S. Luminari, D. Molin, P. Corradini, A. Gallamini, A. Rambaldi, C. Tarella
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD
2025 C. Rusconi, A. Barone, A. Visentin, B. Bianchi, V.R. Zilioli, A. Bernardelli, S. Iadecola, E. Olivari, F.G. Rossi, M. Gotti, C. Cecchetti, B. Puccini, S. Franceschetti, A. Molteni, S. Steffanoni, F. Marino, A. Vanazzi, A. Guidetti, M. Merli, F. Mazzon, A. Marchetti, A. Cellini, C. Muzi, R. Miceli, C. Visco, A. Re, P. Corradini
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
2025 M. Hutchings, A. Sureda, F. Bosch, T.S. Larsen, P. Corradini, A. Avigdor, M.J. Terol, A.R. Dominguez, A. Pinto, A. Skarbnik, R. Cordoba, J.M. Jørgensen, P.L. Zinzani, W. Leung, A. Bottos, D. Li, J. Relf, M. Tandon, G. Sellam, G. Gritti
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
2025 C. Visco, V. Tabanelli, M.V. Sacchi, A. Evangelista, F.M. Quaglia, S. Fiori, R. Bomben, M.C. Tisi, M. Riva, A. Merli, F. Rotondo, C. Fraenza, M.E. Carazzolo, P. Corradini, L. Farina, C. Castellino, A. Castellino, V.R. Zilioli, C. Muzi, F. Piazza, A. Re, S. Hohaus, F.G. Rossi, G. Musuraca, A. Di Rocco, B. Puccini, R. Sciarra, F. Ballerini, F. Cavallo, R. Bruna, R. Moia, A. Moioli, A. Bernardelli, D. Drandi, A. Arcari, F. Merli, G. Gini, R. Freilone, M. Tani, V. Pavone, M. Ladetto, S.A. Pileri, M. Balzarotti